These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 2572313)

  • 21. Tacrine in Alzheimer's disease.
    Davies B; Andrewes D; Stargatt R; Ames D; Tuckwell V; Davis S
    Lancet; 1989 Jul; 2(8655):163-4. PubMed ID: 2567933
    [No Abstract]   [Full Text] [Related]  

  • 22. THA and Alzheimer's disease.
    Hayward L; Brodaty H
    Aust N Z J Psychiatry; 1987 Dec; 21(4):618-9. PubMed ID: 3449055
    [No Abstract]   [Full Text] [Related]  

  • 23. (+/-)-9-Amino-1,2,3,4-tetrahydroacridin-1-ol. A potential Alzheimer's disease therapeutic of low toxicity.
    Shutske GM; Pierrat FA; Cornfeldt ML; Szewczak MR; Huger FP; Bores GM; Haroutunian V; Davis KL
    J Med Chem; 1988 Jul; 31(7):1278-9. PubMed ID: 3385720
    [No Abstract]   [Full Text] [Related]  

  • 24. Tacrine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in Alzheimer's disease.
    Wagstaff AJ; McTavish D
    Drugs Aging; 1994 Jun; 4(6):510-40. PubMed ID: 7521234
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The use of THA for Alzheimer's disease.
    Brodaty H
    Med J Aust; 1990 Jun; 152(11):614. PubMed ID: 2348794
    [No Abstract]   [Full Text] [Related]  

  • 26. FDA queries Alzheimer's trial results.
    Marx JL
    Science; 1988 Feb; 239(4843):969. PubMed ID: 3278380
    [No Abstract]   [Full Text] [Related]  

  • 27. Canadian collaborative study of tetrahydroaminoacridine (THA) and lecithin treatment of Alzheimer's disease: effect on mood.
    Vida S; Gauthier L; Gauthier S
    Can J Psychiatry; 1989 Apr; 34(3):165-70. PubMed ID: 2655861
    [TBL] [Abstract][Full Text] [Related]  

  • 28. WITHDRAWN: Tacrine for Alzheimer's disease.
    Qizilbash N; Birks J; Lopez Arrieta J; Lewington S; Szeto S
    Cochrane Database Syst Rev; 2007 Jul; (3):CD000202. PubMed ID: 17636619
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment for Alzheimer's disease?
    Growdon JH
    N Engl J Med; 1992 Oct; 327(18):1306-8. PubMed ID: 1357552
    [No Abstract]   [Full Text] [Related]  

  • 30. Fee-for-service research on THA: an explanation.
    Summers WK
    N Engl J Med; 1987 Jun; 316(25):1605-6. PubMed ID: 3587296
    [No Abstract]   [Full Text] [Related]  

  • 31. [Effects of amiridin and tacrine, drugs effective in Alzheimer's disease, on synaptosomal uptake of neuromediators].
    Burov IuV; Baĭmanov TD; Maĭsov NI
    Biull Eksp Biol Med; 1992 Apr; 113(4):379-81. PubMed ID: 1356507
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tacrine: first drug approved for Alzheimer's disease.
    Crismon ML
    Ann Pharmacother; 1994 Jun; 28(6):744-51. PubMed ID: 7919566
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Progress report on the Canadian Multicentre Trial of tetrahydroaminoacridine with lecithin in Alzheimer's disease.
    Gauthier S; Bouchard R; Bacher Y; Bailey P; Bergman H; Carrier L; Charbonneau R; Clarfield M; Collier B; Dastoor D
    Can J Neurol Sci; 1989 Nov; 16(4 Suppl):543-6. PubMed ID: 2680009
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Tacrine].
    Dávila C; Viteri C; de Castro P
    Rev Med Univ Navarra; 1997; 41(1):58-64. PubMed ID: 9527715
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neurotransmitter deficits in Alzheimer's disease and in other dementing disorders.
    Mann DM; Yates PO
    Hum Neurobiol; 1986; 5(3):147-58. PubMed ID: 2876973
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Further analysis of the neuropharmacological profile of 9-amino-1,2,3,4-tetrahydroacridine (THA), an alleged drug for the treatment of Alzheimer's disease.
    Drukarch B; Leysen JE; Stoof JC
    Life Sci; 1988; 42(9):1011-7. PubMed ID: 2893967
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vivo detection of neurotransmitter changes in Alzheimer's disease.
    Nordberg A
    Ann N Y Acad Sci; 1993 Sep; 695():27-33. PubMed ID: 7902055
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of the value of therapeutic monitoring of tacrine in Alzheimer's disease.
    Roberts CJ; Ford JM; Truman CA; Scott M; Mäkelä PM; Wilcock GK
    Eur J Clin Pharmacol; 1998; 54(9-10):721-4. PubMed ID: 9923574
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Neurotransmitters in Alzheimer's disease].
    Kristensen MO
    Ugeskr Laeger; 1990 Jul; 152(30):2165-8. PubMed ID: 1975961
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of tetrahydroaminoacridine (tacrine) derivatives and physostigmine in convulsions induced by pentylenetetrazol.
    Herink J; Koupilová M; Hrdina V
    Act Nerv Super (Praha); 1989 Dec; 31(4):303-5. PubMed ID: 2638124
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.